These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 31099875)

  • 21. Oxaliplatin (3 months
    Kim ST; Kim SY; Lee J; Yun SH; Kim HC; Lee WY; Kim TW; Hong YS; Lim SB; Baek JY; Oh JH; Ahn JB; Shin SJ; Han SW; Kim SG; Kang SY; Sym SJ; Zang DY; Kim YH; Choi IS; Kang JH; Kim MJ; Park YS
    J Clin Oncol; 2022 Nov; 40(33):3868-3877. PubMed ID: 35772045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.
    Margalit O; Boursi B; Rakez M; Thierry A; Yothers G; Wolmark N; Haller DG; Schmoll HJ; Shi Q; Shacham-Shmueli E; de Gramont A
    Clin Colorectal Cancer; 2021 Jun; 20(2):130-136. PubMed ID: 33775561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
    Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
    JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?
    Lee JJ; Chu E
    Oncology (Williston Park); 2018 Sep; 32(9):437-42, 444. PubMed ID: 30248163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
    Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
    Ouali K; Turpin A; Neuzillet C; Rousseau B; Garcia-Larnicol ML; Tournigand C; Samalin E; Taieb J; André T; Cohen R
    Clin Colorectal Cancer; 2021 Mar; 20(1):79-83.e4. PubMed ID: 33281064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
    Sha A; Abadi S; Gill S
    J Oncol Pharm Pract; 2018 Oct; 24(7):501-506. PubMed ID: 28714378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study.
    Boyle JM; Kuryba A; Cowling TE; van der Meulen J; Fearnhead NS; Walker K; Braun MS; Aggarwal A
    Int J Cancer; 2022 Jan; 150(2):335-346. PubMed ID: 34520572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
    Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
    Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
    J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
    Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
    PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
    Yoon R; Wilkinson K; Gabriel G; Kadaan N; Roberts T; Lim S; Asghari R; Lee CS; Chua W; Ng W
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):63-70. PubMed ID: 37211922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
    Medinger M; Steinbild S; Mross K
    Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a Shortened Duration of FOLFOX Chemotherapy on the Survival Rate of Patients with Stage II and III Colon Cancer.
    Ji WB; Hong KD; Kim JS; Joung SY; Um JW; Min BW
    Chemotherapy; 2018; 63(1):8-12. PubMed ID: 29130943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.